Stay-On Tirzepatide GI Tolerance Service

A 12-week telehealth coaching and symptom-monitoring service that keeps patients with type 2 diabetes and heart disease on tirzepatide through its GI side effects — with a protocolized fallback switch to dulaglutide — aimed squarely at the drug's 13.2% adverse-event discontinuation rate.